Cannabinoids for use in supressing cancer stem cells

Abstract

It is disclosed a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof:wherein R1 is a linear alkyl group of 3 or 5 carbon atoms, and R2 is:and a pharmaceutical composition comprising the same, for use in the treatment of a disease whose treatment benefits from inhibiting or reducing Notch1 expression levels in cells, and/or benefits from inhibiting or reducing Notch1 levels in cells, and/or benefits from inhibiting or reducing Notch1 signaling dependent proteins levels in cells.As a consequence, present invention also relates to said compound of formula (I), and to the pharmaceutical composition comprising the same, for use in suppressing cancer stem cells, as well as, for use in reducing solid tumor development, metastasis or chemo/radio-resistance, promoted by cancer stem cells.

1 - 15 . (canceled) 
     
     
         16 . A compound selected from the group consisting of (−)-cannabidiol [(−)-CBD], (−)-cannabidivarin [(−)-CDBV], (+)-cannabidivarin [(+)-CBDV] and cannabigerovarin (CBGV): 
       
         
           
           
               
               
           
         
         for use in the treatment of a cancer wherein the cancer is a chemo- or radio-resistant tumor, wherein said chemo- or radio-resistant tumor is a cancer where a chemotherapeutic treatment or radiotherapy has not provided a remission of said cancer, and wherein said cancer is selected from the group consisting of: colon cancer, colorectal carcinoma, colorectal adenocarcinoma, prostate cancer, prostate adenocarcinoma, prostate carcinoma, breast cancer, breast carcinoma, breast adenocarcinoma, triple negative breast cancer, pancreatic cancer and glioma. 
       
     
     
         17 . A compound for use according to  claim 16 , wherein the cancer is selected from the group consisting of: colon cancer, colorectal carcinoma, colorectal adenocarcinoma, breast cancer, breast carcinoma, breast adenocarcinoma and triple negative breast cancer. 
     
     
         18 . A compound for use according to  claim 16 , wherein the cancer is selected from the group consisting of: colon cancer, colorectal carcinoma and colorectal adenocarcinoma. 
     
     
         19 . A pharmaceutical composition comprising at least one compound selected from the group consisting of (−)-cannabidiol [(−)-CBD], (−)-cannabidivarin [(−)-CDBV], (+)-cannabidivarin [(+)-CBDV] and cannabigerovarin (CBGV): 
       
         
           
           
               
               
           
         
         and at least one pharmaceutically acceptable excipient, for use in the treatment of a cancer wherein the cancer is a chemo- or radio-resistant tumor, wherein said chemo- or radio-resistant tumor is a cancer where a chemotherapeutic treatment or radiotherapy has not provided a remission of said cancer, and wherein said cancer is selected from the group consisting of: colon cancer, colorectal carcinoma, colorectal adenocarcinoma, prostate cancer, prostate adenocarcinoma, prostate carcinoma, breast cancer, breast carcinoma, breast adenocarcinoma, triple negative breast cancer, pancreatic cancer and glioma. 
       
     
     
         20 . A pharmaceutical composition for use according to  claim 19 , wherein the cancer is selected from the group consisting of: colon cancer, colorectal carcinoma, colorectal adenocarcinoma, breast cancer, breast carcinoma, breast adenocarcinoma and triple negative breast cancer. 
     
     
         21 . A pharmaceutical composition for use according to  claim 19 , wherein the cancer is selected from the group consisting of: colon cancer, colorectal carcinoma and colorectal adenocarcinoma. 
     
     
         22 . A pharmaceutical composition for use according to  claim 19 , wherein said pharmaceutical composition is administered together with, prior to, or subsequently to, a radiotherapeutic treatment, a chemotherapeutic treatment or an immunotherapeutic treatment. 
     
     
         23 . A pharmaceutical composition for use according to  claim 19 , further comprising at least one additional active compound or therapeutic ingredient. 
     
     
         24 . A pharmaceutical composition for use according to  claim 23 , wherein said additional active compound or therapeutic ingredient is selected from the group consisting of: a CAR-T cell therapy, a CAR-NK cell therapy, a monoclonal antibody with anti-cancer activity, a HIF pathway inhibitor and a chemotherapeutic agent.